Skip to content

Agios Pharmaceuticals AGIO Professional service fees

Professional service fees at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.16B+18.1%
Enterprise value$2.08B+15.2%
P/S32.7×-16.7×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%
Debt / equity0.0×
Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's professional service fees.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's professional service fees?
Agios Pharmaceuticals (AGIO) reported professional service fees of $2.77M in Q1 2026.
How has Agios Pharmaceuticals's professional service fees changed year-over-year?
Agios Pharmaceuticals's professional service fees increased by 64.8% year-over-year, from $1.68M to $2.77M.
What is the long-term trend for Agios Pharmaceuticals's professional service fees?
Over 5 years (2020 to 2025), Agios Pharmaceuticals's professional service fees has grown at a 4.5% compound annual growth rate (CAGR), from $2.9M to $3.61M.